BIX-01294 is an inhibitor of G9a Histone Methyltransferase with IC₅₀ of 1.9 μM.

IC50: 1.9 μM (G9a Histone Methyltransferase)

BIX-01294 (4.1 μM) treatment of G9anull ES cells results in a further reduction in H3K9me2 levels. BIX-01294 reduces H3K9me2 at several G9a target genes^[1]. BIX-01294 (5 µM) reduces levels of global H3K9 methylation in pronuclear- and 2-cell-stage embryos. Embryos transiently exposed to BIX-01294 have a reduced ability to establish pregnancy^[2]. BIX-01294 (1 µg/mL) causes reduction in the BrdU incorporation of fetal PASMCs. BIX-01294 treatment decreases the PASMCs migration induced by PDGF^[3].

• [1]. Kubicek S, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell. 2007 Feb 9;25(3):473-81.

  [2]. Park KE, et al. IVMBIX-01294, an inhibitor of the histone methyltransferase EHMT2, disrupts histone H3 lysine 9 (H3K9) dimethylation in the cleavage-stage porcine embryo. Reprod Fertil Dev. 2012;24(6):813-21.

  [3]. Yang Q, et al. BIX-01294 treatment blocks cell proliferation, migration and contractility in ovine foetal pulmonary arterial smooth muscle cells. Cell Prolif. 2012 Aug;45(4):335-44.

Test compounds are diluted to 12 μg/mL in 50 mM Tris-HCl pH 8.5 containing 4% DMSO and 10 μL is dispensed into the wells. Blank and control wells receive only compound buffer. GST-G9a at 10 μg/mL and SAM at 40 μM are diluted in 50 mM Tris HCl pH 8.5/10 mM DTT and added in a volume of 20 μL. Blank wells receive Tris/DTT buffer only. The reactions are initiated by the addition of 800 nM H3(1-20)-cysbiotin substrate in 50 mM Tris pH 8.5 in a volume of 10 μL, and incubated at room temperature for 60 minutes. The plates are washed 3 times with 100 μL of ish Buffer (50 mM Tris pH 7.4, 150 mM NaCl, 0.05% Tween 20, 0.2% BSA). Next, 50 μL of luoroimmunoassay (FI) Buffer (50 mM Tris HCl pH 7.8, 150 mM NaCl, 0.05% Tween 40, 25 μM DTPA, 0.2% BSA, 0.05% BGG) containing 5 ng α-2X-di-meth H3-K9 and 5 ng goat anti-rabbit Eu chelate is added to all wells of the plate, and the platei s incubated for an additional hour at room temperature. The plates are washed 3 times with 100 μL of ish Buffer, and 50 μL of Enhancement Solution is added to each well. Time resolved fluorescence is measured after 45 minutes on a Viewlux Microplate Imager imaging for 15 seconds with a 354 μs window, 400 μs delay, excitation at 360 nm, and emission at 618 nm. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Briefly, fetal PASMCs are plated in 96-well plates and starved for 24 h at 0.1% serum containing medium. PDGF-BB is added for 24 h at the indicated concentrations in the presence or absence of BIX-01294. BrdU label solution is added to each well 18 h prior to analysis. Denaturing solution is added to each well for 30 min at room temperature after removing the contents of wells. Then, anti-BrdU antibody is added to each well and incubated for 1 h and peroxidase goat anti-mouse IgG HRP conjugate is added in the well for 30 min at room temperature. The absorbance is read at 450-540 nm on a Glomax Multiple Detection System. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

• [1]. Kubicek S, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell. 2007 Feb 9;25(3):473-81.

  [2]. Park KE, et al. IVMBIX-01294, an inhibitor of the histone methyltransferase EHMT2, disrupts histone H3 lysine 9 (H3K9) dimethylation in the cleavage-stage porcine embryo. Reprod Fertil Dev. 2012;24(6):813-21.

  [3]. Yang Q, et al. BIX-01294 treatment blocks cell proliferation, migration and contractility in ovine foetal pulmonary arterial smooth muscle cells. Cell Prolif. 2012 Aug;45(4):335-44.

490.64

C₂₈H₃₈N₆O₂

935693-62-2

Room temperature in continental US; may vary elsewhere

10 mM in DMSO

* "<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">